NSE: PFIZER | BSE: 500680

Expensive Performer

Download real time

5613.30 28.00 (0.50%)

51.67% Gain from 52W Low

45,496 NSE+BSE Volume

NSE 30 May, 2025 3:31 PM (IST)

25,679.6

Market Cap

High in industry

0.3

Beta 1Year

Very Low volatility

Pfizer Ltd. share price target and research reports

Name: Latest research reports of Pfizer Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Pfizer Ltd.
Rating: 5
Author: ICICI Securities Limited

Latest analyst research reports with target prices and PDF download for PFIZER, BSE:500680 Pfizer Ltd.

Pfizer Ltd.

04 Feb 2022

5613.30

0.50%

Pfizer Ltd

Buy: Pfizer Ltd.

Target

ICICI Securities Limited

About the stock: Pfizer collectively addresses 15 therapy areas in the domestic formulations with a portfolio of over 150 products that include therapeutics & vaccines. The company has been continuously restructuring its portfolio in the last...

Number of FII/FPI investors decreased from 151 to 129 in Mar 2025 qtr

Pfizer Ltd.

09 Nov 2021

5613.30

0.50%

Pfizer Ltd

Buy: Pfizer Ltd.

Recommendation Target

ICICI Securities Limited

About the stock: Pfizer collectively addresses 15 therapy areas with a portfolio of over 150 products that include therapeutics & vaccines. The company has been continuously restructuring its portfolio in the last few years to improve the...

Pfizer Ltd. has gained 31.51% in the last 1 Month

Pfizer Ltd.

29 Jul 2021, 12:00AM

5613.30

0.50%

Pfizer Ltd

Hold: Pfizer Ltd.

Recommendation Target

ICICI Securities Limited

Pfizer Ltd. is trading above all available SMAs

Pfizer Ltd.

27 May 2021

5613.30

0.50%

Pfizer Ltd

Buy: Pfizer Ltd.

Target

ICICI Securities Limited

Besides legacy NLEM/GST related adjustments, Pfizer has been continuously restructuring its portfolio in the last few years to improve the productivity of its core brands and also in accordance with development at the parent level. Despite stagnant turnover growth (FY16-21 CAGR of ~2%), the company has delivered margin improvement on a fairly consistent basis (FY21 EBITDA margin of 31.8% vis--vis FY16 EBITDA margins of 21.5%;...

Pfizer Ltd. has gained 38.60% in the last 3 Months

Pfizer Ltd.

14 Dec 2020

5613.30

0.50%

Daily Fundamental View:14 December 2020

Daily Note: Pfizer Ltd.

Axis Direct

Asian markets are trading in the green as investors react to the approval of Pfizer's Covid-19 vaccine and data from Japan showed improving business sentiment in three months to December. Nikkei is trading higher by 0.70%; Hang Seng is trading higher by 0.04% and Shanghai is trading higher by 0.15..

Pfizer Ltd. is trading above all available SMAs

Pfizer Ltd.

02 Nov 2020

5613.30

0.50%

Pfizer Ltd

Buy: Pfizer Ltd.

Target

ICICI Securities Limited

Besides legacy NLEM/GST related adjustments, Pfizer has been continuously restructuring its portfolio in the last few years to improve the productivity of its core brands and also in accordance with development at the parent level. Despite stagnant turnover growth (FY15-20 CAGR of ~3%), the company has delivered margin improvement on a fairly consistent basis (FY20 EBITDA margins 26.6% vis--vis FY15 EBITDA margins of 20.7%;...

Pfizer Ltd. is trading above all available SMAs

Pfizer Ltd.

04 May 2020

5613.30

0.50%

Ashika - Stock Picks - Pfizer Ltd. - May 2020

Buy: Pfizer Ltd.

Ashika Research

produce millions of vaccines by end2020. The two companies are working on four possible vaccines against the new coronavirus, and launched clinical trials using volunteers in Germany earlier this month and hope to begin a U.S. trial soon, pending approval by regulators. The companies were moving forward to ramp up clinical trials and manufacturing capabilities in parallel to be able to...

Number of FII/FPI investors decreased from 151 to 129 in Mar 2025 qtr

Pfizer Ltd.

20 Apr 2020

5613.30

0.50%

Pfizer Ltd

Buy: Pfizer Ltd.

Target

ICICI Securities Limited

On the business front, despite the nationwide lockdown, domestic growth is expected to remain more or less stable. Exports growth, barring for one or two months due to congestion in all major ports globally, is also expected to remain strong due to 1) currency benefit, 2) slowdown in competition due to delay in new approvals that will be beneficial for existing players and 3) expected demand continuum across the world despite Covid-19. Some windfall is also expected in some critical productsa case in point is Hydroxychloroquine, a malaria drug that is likely to be repurposed as a prophylaxis for Covid-19 treatment in some cases....

Pfizer Ltd. is trading above all available SMAs

Pfizer Ltd.

31 Oct 2019

5613.30

0.50%

Pfizer Ltd

Buy: Pfizer Ltd.

Target

ICICI Securities Limited

Pharma MNCs with domestic focus continue to drive investor's interest on the back of 1) consistency in stable growth despite higher competition and regulatory changes, 2) strong focus on legacy power brands as well as introduction from the global parent's stable, 3) consistent free cash-flow generation, 4) debt-free balance sheet and strong core RoEs and 5) healthy dividend payout track record. The domestic pharma industry is expected to grow in the range of 9-11% per annum. Issues such as NLEM and other regulatory aspects are mostly in the price. On the flip side, the looming...

Pfizer Ltd. has gained 31.51% in the last 1 Month

Pfizer Ltd.

10 Sep 2018

5613.30

0.50%

Pfizer

Hold: Pfizer Ltd.

Recommendation Target

Centrum Broking

Strong revenue growth: Pfizer's revenues are likely to grow faster than the market growth due to strong growth of its major brands. The growth was contributed by its major brands namely: Becosules, Ovral-L, Corex-Dx,Wysolone, Magnex, Neksium and Dolonex. We expect the company to report better revenue growth in FY19, led by the launch of a series of products as line extensions under the Corex brand name and the recent launch of Meronem and Neksium in India. The management indicated the launch of 3-4 new products per annum. Pfizer's 17 brands are in No.1 position in the...

Number of FII/FPI investors decreased from 151 to 129 in Mar 2025 qtr

Is Pfizer Ltd. worth buying?

203 Votes:

Buy 74.88%

Sell 15.27%

Hold 9.85%